Table 3.
Angiographic, seizure-related and hematologic complications in the series of CIAC/CIAC + BBBD patients treated in Sherbrooke, from 2000–2015. A total of 3583 procedures in 722 patients were accomplished.
| Angiographic + Vascular Complications | Number of Event MRI + Angiographic Findings | MRI Findings | Symptomatic Lesions (the Lesion was Accompanied by Clinical Symptoms) | Asymptotic (Lesion Found at MRI or Angiography without Consequent Symptoms) | ||
|---|---|---|---|---|---|---|
| Dissections | 5 | 1 | 0 | 5 | ||
| Stenosis | 9 | 2 | 0 | 9 | ||
| Occusions | 3 | 2 | 2 | 1 | ||
| Hemorragic lesions | 5 | 5 | 1 | 4 | ||
| Lacunar Strokes | 38 | 38 | 20 | 18 | ||
| Strokes | 6 | 6 | 4 | 2 | ||
| Total of events on 3586 procedures | 66 (1.84%) | 54 (1.5%) | 27 (0.75%) | 39 (1.08%) | ||
| Focal Seizures (# of Events) | Generalized Seizures (# of Events) | Lymphomas | Metastasis | Glial Tumors | MTX | Carboplatin |
| 65 | 9 | 23 | 4 | 12 | 62 | 12 |
| 74 seizure events (2%) | 39 patients (5.4%) | |||||
| Hematologic Toxicites (per NCIC Toxicity Criteria) | Grade 1 | Grade 2 | Grade 3 | Grade 4 | Total | |
| Neutropenia | 70 (9.7%) | 67 (9.3%) | 22 (3.1%) | 21 (2.9%) | 180 (24.9%) | |
| Thrombocytopenia | 43 (5.9%) | 37 (5.1%) | 35 (4.9%) | 21 (2.9%) | 136 (18.8%) | |
| Anemia | 115 (15.9%) | 78 (10.8%) | 25 (3.5%) | 10 (1.4%) | 228 (31.6%) | |
| Total | 228 (31.6%) | 182 (25.2%) | 82 (11.4%) | 52 (7.2%) | ||